Combination therapy may offer new therapeutic avenue for previously-treated NSCLC and kidney cancer patients

Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer and kidney cancer.
Read More

>>Hollywood's Exotic Secret For Healthy Weight Loss